- Molecular NameEpirubicin
- SynonymNA
- Weight557.552
- Drugbank_IDDB00445
- ACS_NO56420-45-2
- Show 3D model
- LogP (experiment)0.455
- LogP (predicted, AB/LogP v2.0)0.91
- pka7.7
- LogD (pH=7, predicted)-0.2
- Solubility (experiment)0.093 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.32
- LogSw (predicted, AB/LogsW2.0)0.32
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors7
- No.of HBond Acceptors12
- No.of Rotatable Bonds6
- TPSA206.07
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anthracycline drug used for chemotherapy.
- Absorption_valueN/A
- Absorption (description)Pharmacokinetics vary widely between patients.
- Caco_2N/A
- Bioavailability0.0
- Protein binding77.0
- Volume of distribution (VD)13~52 L/kg. Steady state, 1000 L/m2.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic glucuronidation and oxidation. Epirubicin is rapidly and extensively distributed into body tissues after intravenous administration. High concentrations occur in tumour tissues. It also concentrates in red blood cells and therefore concentrations in blood are substantially higher than those in plasma. It does not cross the blood–brain barrier. Epirubicin undergoes extensive metabolism, primarily in the liver (but also in other organs and cells including red blood cells), to form epirubicinol (13-hydroxyepirubicin) which has a very low degree of cytotoxic activity and appreciable amounts of glucuronide derivatives. 7-Deoxyaglycones have also been detected in plasma of patients treated with epirubicin.
- Half life30~40 h
- ExcretionEpirubicinol is eliminated mainly in bile. About 10 to 20% of a dose is recovered in urine within 48 h as the unchanged drug, epirubicinol, or as the glucuronide metabolite. 40% is recovered in bile in 72 h.
- Urinary ExcretionN/A
- Clerance50 L/h/m2; 0.9 L/min.
- ToxicityMyelosuppression is the major acute dose-limiting toxicity and cardiotoxicity is the most important cumulative dose-limiting toxicity.
- LD50 (rat)N/A
- LD50 (mouse)N/A